Scarica l'app Stockscreener
5.59
0.18%
0.010
Pre-mercato:
5.48
-0.11
-1.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind stock gets Buy rating reaffirmation from Truist at $9 target - Investing.com
Avant Technologies Leads Transformation in Healthcare Market - Intellectia AI
MannKind (NASDAQ:MNKD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates 'Buy' Rating for MNKD with $11 Target | MNKD Stock News - GuruFocus
MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Finviz
MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza - Stocktwits
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? - Asianet Newsable
MannKind stock rises after FDA approves updated Afrezza label - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin - Investing.com
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Yahoo Finance
MannKind’s Volatile Week: Can MNKD Justify The Recent Rebound In Its Stock? - AD HOC NEWS
Growth Report: What hedge funds are buying MannKind CorporationJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.
Investment Recap: Is MannKind Corporation backed by strong institutional buying - baoquankhu1.vn
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative - Yahoo Finance
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1% - MarketBeat
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Insider Monkey
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com Australia
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
How MannKind Corporation stock reacts to global recession fears2025 Volatility Report & Risk Managed Trade Strategies - Улправда
MannKind stock jumps on 2026 catalysts - Investing.com
Can MannKind Corporation stock deliver surprise earnings beatInsider Buying & Advanced Technical Analysis Signals - ulpravda.ru
MannKind Corp stock hits 52-week high at 6.33 USD - Investing.com
MannKind outlines 2026 growth drivers with key FDA decisions ahead - Investing.com
MannKind Provides Business Updates and 2026 Growth Drivers - Yahoo Finance
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - MSN
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD - MarketBeat
Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):